Agenus Reports Q4 2024 Results, Strengthens BOT/BAL Program Agenus Reports Q4 and Full-Year 2024 Financial and Operational Results, Implements Strategic Cost Reductions to Enhance Sustainability of BOT/BAL Program Agenus Inc.…
RoslinCT and Ayrmid Pharma Ltd. Plan Strategic Partnership for Omisirge® Manufacturing Ayrmid Pharma Ltd., a pioneering company in cell therapy focused on transforming cells into powerful therapeutics, and RoslinCT, a…
NationsBenefits® Partners with TS Emporium to Expand Access to Culturally Relevant Health Products NationsBenefits®, a leading provider of supplemental benefits and healthcare fintech solutions, has announced a strategic partnership with…
Noramco Group Invests $25M in Halo Pharma for Sterile Injectables The Noramco Group Invests $25 Million in Halo Pharma’s Whippany Facility to Establish Sterile Injectable Manufacturing The Noramco Group, a…
Care Access Acquires Brazil-Based Clinical Research Center CEMEC Care Access, a globally recognized healthcare and clinical research organization, has announced the successful acquisition of Centro Multidisciplinar de Estudos Clínicos (CEMEC),…
WAINZUA (Eplontersen) Receives EU Approval for Hereditary ATTR Amyloidosis Treatment Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that WAINZUA (eplontersen), developed in collaboration with AstraZeneca, has been approved by the…
ZYUS Life Sciences Closes Unsecured Loan and Amends Previous Loans ZYUS Life Sciences Corporation (“ZYUS” or the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the research, development,…
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for serious and rare…
NeoGenomics Acquires Pathline to Strengthen Oncology Testing in the Northeast NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology testing services, has announced its acquisition of Pathline,…
Agomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn’s Disease Agomab Therapeutics NV (“Agomab”), a biotechnology company focused on developing innovative treatments for fibrotic diseases, has…
Virpax Explores MET Technology for Intranasal COVID-19 Vaccine Development Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative, non-addictive treatments for pain…
UroGen Pharma Reports Inducement Grants Under Nasdaq Rule 5635(c)(4) UroGen Pharma Ltd. (Nasdaq: URGN), a leading biotechnology company focused on developing and commercializing innovative therapies for urothelial and specialty cancers,…